Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with or without platinum-based chemotherapy versus chemotherapy for advanced or metastatic urothelial carcinoma
NL-OMON45288Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, cisplatin, carboplatin and gemcitabine in transitional cell carcinoma (TCC) and bladder cancer (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Jul 2017; status: active, not recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON45288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45288.